A 66-year-old man presented to the emergency department for painful and pruritic ulcerative cutaneous lesions involving his back, nose, lips, and mucosal lesions involving his oral cavity and oropharynx. What is your diagnosis?
This case report describes the occurrence of a decrease of anti-DSG3, but not anti-DSG1, after cessation of sitagliptin treatment in a patient with pemphigus vulgaris.
This case report describes esophagitis dissecans superficialis endoscopically induced in a patient with pemphigus vulgaris and gastrointestinal complaints.
A 64-year-old African American woman presented with crusted scalp plaques, erosive stomatitis, and multiple bullae, erosions, and hyperpigmented patches on her trunk and extremities. Her serum creatinine level was 7.1 mg/dL; a complete blood cell count was unremarkable. What would you do next?
In this case series evaluating intralesional rituximab injections for pemphigus vulgaris in 3 patients, the treatment had no adverse effects, reduced the amount of drug administered, and was less expensive than intravenous administration.
This case describes opportunistic infection with Trichosporon inkin refractory to conventional antifungal treatment.
This case series suggests the use of a combination of rituximab and topical corticosteroids in the treatment of pemphigus vulgaris.
Nakahara et al describe a patient with pemphigus vulgaris in remission, who had a high enzyme-linked immunosorbent assay (ELISA) index for anti–desmoglein 3 antibody while the indirect immunofluorescence (IIF) result was negative. The authors report this case focusing on the discrepancy between ELISA and IIF findings, as well as on the specific characteristics of the patient’s autoantibodies evaluated by newly developed methods.
Ellebrecht et al describe the use of veltuzumab, a second-generation humanized anti-CD20 antibody, in a patient with pemphigus vulgaris.
Rahbar and coauthors evaluate clinical pemphigus disease activity measurements.
You currently have no searches saved.
Create a personal account or sign in to: